In this issue:
BCI predictive of extended endocrine therapy benefit
No delay of bone metastasis with denosumab
Atezolizumab + nab-paclitaxel in PD-L1+ tumours
Abemaciclib + fulvestrant after prior endocrine therapy
CDK4/6 inhibitor + aromatase inhibitor in older women
Impact of treatment on QoL in breast cancer survivors
St. Gallen consensus guidelines for early breast cancer
Meta-analysis supports endocrine therapy + targeted therapy
Please login below to download this issue (PDF)